7月14日 - ** 药物开发商 MiNK Therapeutics INKT.O 股价盘前下跌 31%，至 44.30 美元，前一交易日涨幅超过 700
** H.C. Wainwright分析师Emily Bodnar称，该公司正在逆转上周五癌症治疗试验数据带来的涨势
** INKT 的实验性异体细胞疗法 agenT-797 显示，一名晚期睾丸癌患者的病情得到完全缓解，论文发表在《肿瘤基因》（Oncogene）杂志上。
** 公司表示，中期数据有望在未来几个月内公布，研究正在招募患者
** 截至上次收盘，该公司股价累计上涨 820.79
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.